Cradle is an AI protein-engineering platform for biopharma and industrial biotech teams: it generates candidate protein variants based on desired properties and optimizes them through machine learning models that retrain on every round of a customer’s own experimental (wet-lab) data, guiding the next design cycle based on what the lab actually measured last time.
Multi-property co-optimization is what makes this genuinely different from a single-objective prediction tool – Cradle can simultaneously optimize activity, binding, stability, expression, and custom properties a team defines itself, on the principle that “if you can measure it, you can optimize it.” Teams can also train organization-specific predictor models on their own proprietary data, with that data kept private and explicitly never used to train models for other Cradle customers – a structural guarantee rather than just a policy statement, which matters directly for biopharma teams protecting genuinely proprietary discovery data.
Cradle reports 2-12x faster development timelines for teams developing antibodies, enzymes, vaccines, and peptides, with AI models the company describes as improving “every two weeks.” The platform is enterprise-focused, including SOC 2 compliance, SSO support, and dedicated scientific support; pricing is not disclosed and requires contacting the company.
